Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NRSNW - NeuroSense Therapeutics Ltd - Warrants (09/11/2026)


Previous close
0.17
0   0%

Share volume: 101
Last Updated: Wed 28 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.17
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
12.51%
1 Month
28.21%
3 Months
68.82%
6 Months
-43.33%
1 Year
-31.73%
2 Year
-41.36%
Key data
Stock price
$0.17
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.07 - $0.65
52 WEEK CHANGE
-$0.10
MARKET CAP 
17.329 M
YIELD 
N/A
SHARES OUTSTANDING 
1.846 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$800
AVERAGE 30 VOLUME 
$1,483
Company detail
CEO:
Region: US
Website: neurosense-tx.com
Employees: 18
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa

Recent news